	US 12,226,398 B2
	FABP4 as a therapeutic target in skin diseases
Tali Garin-Shkolnik, Timrat (IL)
Assigned to TICURE LTD., Netanya (IL)
Filed by TICURE LTD., Netanya (IL)
Filed on Dec. 16, 2021, as Appl. No. 17/553,253.
Application 17/553,253 is a division of application No. 16/344,705, granted, now 11,229,624, previously published as PCT/IL2017/051168, filed on Oct. 25, 2017.
Claims priority of provisional application 62/412,487, filed on Oct. 25, 2016.
Prior Publication US 2022/0096435 A1, Mar. 31, 2022
Int. Cl. A61K 31/403 (2006.01); A61K 31/415 (2006.01); A61K 31/7105 (2006.01); A61K 31/713 (2006.01); A61P 17/00 (2006.01); C12Q 1/6883 (2018.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01)

CPC A61K 31/403 (2013.01) [A61K 31/415 (2013.01); A61K 31/7105 (2013.01); A61K 31/713 (2013.01); A61P 17/00 (2018.01); C12Q 1/6883 (2013.01); A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61K 45/06 (2013.01); G01N 2800/20 (2013.01)]

18 Claims

1. A method for treating or preventing a skin disease in a subject in need thereof having, in the skin thereof, keratinocytes or inflammatory cells that overexpress FABP4, said method comprising administering to said subject a therapeutically effective amount of at least one small molecule FABP4 inhibitor or a pharmaceutical composition thereof,

wherein said at least one small molecule FABP4 inhibitor each independently has a main ring structure which has a 3-10 membered saturated, unsaturated, or aromatic carbocyclic or heterocyclic ring, or a system of two or more such rings that are fused, bridged, or spiro-connected, and wherein said main ring structure is optionally substituted at one or more of its possible substitution positions; and

wherein said skin disease is characterized by the presence, in the skin, of keratinocytes or inflammatory cells overexpressing FAPB4.